Загрузка...
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies (Abs) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) Abs, are effective for patients with various cancers. However, low response rates to ICI monotherapies and even hyperprogressive disease (HPD) have limited the clinical applica...
Сохранить в:
| Опубликовано в: : | Mol Cancer |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7195736/ https://ncbi.nlm.nih.gov/pubmed/32359357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-020-01200-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|